ClinicalTrials.gg
CompletedNCT01625598CDDRUpdated Apr 22, 2014

Computer Detection of Diabetic Retinopathy Compared to Clinical Examination

An observational study in Diabetic Retinopathy, sponsored by Digital Diagnostics, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-22.

Sponsored by Digital Diagnostics, Inc. · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

The hypothesis is that computer detection of the severity of diabetic retinopathy including the presence of clinically significant macular edema is not inferior to the detection using a dilated eye examination by a Board-certified ophthalmologist.

Read the detailed description

The project is a multicenter, observational study to compare the accuracy of the IDX-DR computer detection system to board certified ophthalmologists performing dilated eye examination at identifying between no or mild NPDR without clinically significant diabetic macular edema from more than mild NPDR with or without CSDME. Approximately 400-600 persons with diabetes will be recruited through 5 clinical centers. The ophthalmologist who examines the patient will evaluate and record the status of the eye based on his/her clinical examination. The study subjects will then have two fundus photographs taken of each eye. The photographic images will be transferred to a central Reading Center at the University of Pennsylvania and interpreted by professional graders. The Reading Center will then transfer the images to IDx-DR, the computer detection system. IDx-LLC, the Sponsor of this study, will have no access to the images. Data from the Reading Center interpretation will be considered the "gold standard". The results of the clinical examination and IDX-DR will be compared against this gold standard as well as against each other.

02

Conditions studied

  • Diabetic Retinopathy

Browse trials for

Keywords

  • Nonproliferative diabetic retinopathy
  • diabetic macular edema
  • proliferative diabetic retinopathy
  • ophthalmologists
  • dilated eye exam
03

In context

Diabetic Retinopathy

791 studies on the registry are indexed under Diabetic Retinopathy; 139 are open to participants now.

This study's enrollment of 600 is above the median of 150 across 268 observational studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

Digital Diagnostics, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Persons with diabetes, eighteen years of age or older, who have been referred to an ophthalmologists for a dilated eye examination to detect diabetic retinopathy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a diagnosis of diabetes mellitus
  • subject understands study and has signed informed consent
  • no history of any other retinal vascular disease, glaucoma, or other disease that may affect the appearance of the retina or optic disc (refractive error and ocular surface disease are allowed);
  • other than cataract surgery, no history of intraocular surgery, ocular laser treatments for any retinal disease, or ocular injections for diabetic macular edema or proliferative disease
  • no media opacity precluding good retinal photography
  • age 18 or older

Exclusion criteria

Exclusion Criteria:

  • no diagnosis of diabetes mellitus
  • potential subject cannot understand study or informed consent
  • a history of retinal vascular disease other than due to diabetic retinopathy, glaucoma, or other disease that may affect the appearance of the retina or optic disc
  • previous intraocular surgery other than cataract; previous laser to the retina; or previous intraocular injections for the treatment of diabetic retinopathy
  • a media opacity in either eye that is severe enough to preclude good retinal photography
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
600 participants (actual)

Groups and cohorts

  • People with diabetes

    People with diabetes who are referred to an ophthalmologist for a dilated eye examination

    Procedure: Photography of the retina · Procedure: Retinal photography

Interventions

  • ProcedurePhotography of the retina

    Every subject will undergo photography of the retina in both eyes

  • ProcedureRetinal photography

    Device Subjects will have photography of both eyes

06

What researchers measure

Primary outcomes

  1. Sensitivity of detecting moderate non proliferative diabetic retinopathy or more severe DR and/or significant macular edema on a person-specific basis.

    If the interval excludes differences of 10% or more (IDx worse than clinical examination), then the IDx system will be considered non-inferior to clinical examination by ophthalmologists. If IDx is non-inferior to clinical examination, a two-sided test of the null hypothesis that the difference in sensitivities is 0 will be conducted to determine if the IDX is superior to clinical examination. 24 McNemar's test for paired proportions will be used to test the difference in proportions.

    Time frame: Recruitment over 4 months

Secondary outcomes

  1. Specificity (true negatives divided by true negatives plus false positives) at detecting more than moderate non proliferative diabetic retinopathy and/or significant macular edema on a person-specific basis.

    Secondary Outcome Variables: * Specificity on a person-specific basis * Sensitivity on an eye-specific basis \[Clinical examination only\] * Specificity on an eye-specific basis \[Clinical examination only\]

    Time frame: Four months

  2. Sensitivity on an eye-specific basis [Clinical examination only]

    Analysis of secondary outcomes will follow the same approach as for the primary outcome analysis of paired proportions as described above for the comparison of person-specific sensitivity.

    Time frame: Four months

  3. Specificity on an eye-specific basis [Clinical examination only]

    Analysis of secondary outcomes will follow the same approach as for the primary outcome for analysis of paired proportions as described above for the comparison of person-specific sensitivity.

    Time frame: Four months

07

Study locations

7 sites
  • Barnet Dulaney Perkins Eye Center
    Mesa, Arizona 85206, United States
  • Barnet Dulaney Perkins Eye Center
    Phoenix, Arizona 85016, United States
  • Iowa Eye Center
    Cedar Rapids, Iowa 52403, United States
  • University of Iowa Department of Ophthalmology and Visual Sciences
    Iowa City, Iowa 52242, United States
  • Retina Consultants of Houston
    Houston, Texas 77030, United States
  • Robert Cizik Eye Clinic - University of Texas Houston
    Houston, Texas 77030, United States
  • Retina Consultants of Houston
    Houston, Texas 77090, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2012
First posted
Jun 21, 2012
Start
Apr 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
Apr 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01625598
Lead sponsor
Digital Diagnostics, Inc.
Collaborators
University of Pennsylvania, University of Iowa, The University of Texas Health Science Center, Houston, Iowa Eye Center, Cedar Rapids IA, VitreoRetinal Surgery, PA, Retina Consultants Houston, Barnet Dulaney Perkins Eye Centers
Responsible party
Sponsor
First posted
Jun 21, 2012
Start date
Apr 2012
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Apr 22, 2014

Study contacts

Jordan Graff, MD
principal investigator · Barnet Dulaney Perkins Eye Center - Phoenix & Mesa AZ
Brian Privett, MD
principal investigator · Iowa Eye Center, Cedar Rapids IA
Timothy Johnson, MD
principal investigator · University of Iowa, Iowa City IA
James Major, MD
principal investigator · Retina Consultants of Houston - Houston TX (2 locations)
Judianne Kellaway, MD
principal investigator · Robert Cizik Eye Center - University of Texas Houston
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion